How to Treat: Rheumatoid arthritis

+How to treat
In print

How to Treat: Rheumatoid arthritis

By Kate O’Mahony and Ravi Suppiah
FRAZ-Rheumatism-2022

Rheumatoid arthritis is a common condition, seen in approximately 1 per cent of the general population. It can start at any age, women are three times more likely to be affected than men, and it is most common in those of European and North American descent. Historically, it was a major cause of chronic pain, disability, loss of independence and even reduced life expectancy. With the widespread use of disease-modifying anti-rheumatic drugs, it is now a very treatable chronic disease with a life expectancy and quality of life approaching that of the general population, explain Kate O’Mahony and Ravi Suppiah

This continuing medical education activity has been endorsed by the RNZCGP and has been approved for up to 1 CME credit for continuing professional de, Educate small, BACK panel - grey
References
  1. MacGregor AJ, Snieder H, Rigby AS, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43(1):30–37.
  2. Matsushita M, Yamaji K, Tamura N. Extra-articular manifestations of rheumatoid arthritis. Juntendo Medical Journal 2020;66(1):21–26.
  3. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797.
  4. Whiting PF, Smidt N, Sterne JA, et al. Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010;152:456.
  5. Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 2011;108(42):17372–77.
  6. Enthesitis and Enthesopathy. The Enthesis and Bone Erosion in Rheumatoid Arthritis. December 2012. https://enthesis.info/pathology/sec_and_joint_erosion.html
  7. Colebatch AN, Edwards CJ, Østergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 2013;72(6):804–14.
  8. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69(9):1580–88.
  9. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76:17–28.
  10. Prevoo ML, van ‘t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38(1):44–48.
  11. Arthritis Research UK. Complementary and alternative medicines for the treatment of rheumatoid arthritis, osteoarthritis and fibromyalgia. October 2012. https://www.versusarthritis.org/media/1337/complementary-and-alternative-medicines-report.pdf
  12. Landewé RBM, Kroon FPB, Alunno A, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis 2022:annrheumdis-2021-222006. 23 February online.